StockData

Pluri vs Scinai Immunotherapeutics

PLUR and SCNI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PLUR and SCNI compare

Scinai Immunotherapeutics grew revenue faster over the last twelve months (99.2% versus −24.0% for Pluri).

Scinai Immunotherapeutics keeps more of each dollar of sales as profit, with a net margin of −634% compared with −2345% at Pluri.

Scinai Immunotherapeutics scores higher on the StockData Score (6 against 2 for Pluri), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPLURSCNI
Size and price
Market cap$12.1M–
Share price$0.980$0.372
Change, 1 year−74.6%−96.2%
Change, 5 years−95.4%−100.0%
Beta (5Y)0.051.20
Employees9245
StockData Score
Total score26 (better)
Valuation score00
Growth score11
Performance score1 (better)0
Health score05 (better)
Dividend score00
Valuation
P/S11.9×–
FCF yield−167%–
Growth
Revenue growth (TTM)−24.0%99.2% (better)
Net income growth (TTM)–−273%
Profitability
Gross margin44.6% (better)−202%
Operating margin−2455%−575% (better)
Net margin−2345%−634% (better)
FCF margin−1990%−462% (better)
Return on equity–−84.8%
Return on invested capital–−74.7%
Financial health
Debt / equity–0.00
Interest coverage−26.8×–
Current ratio0.271.56 (better)
Altman Z-score−30.53–
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−41.9%–
Shareholder yield−41.9%–
Ownership
Held by institutions0.22%–
Held by insiders54.6%7.4%
Insider net buying, 12 months$1.3M–
Short interest, % of float1.4%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.